Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

hydrocortisone acetate and pramoxine hydrochloride

×

Overview

What is Pramosone E Cream 2.5%?

Pramosone E Cream 2.5%

Topical corticosteroids are anti-inflammatory and anti-pruritic agents. The structural formula, the chemical name, molecular formula and molecular weight for active ingredients are presented below.

hydrocortisone acetate Pregn-4-ene-3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy-, (11-beta)- C H O ; mol. wt. 404.50

pramoxine hydrochloride 4-(3-(p-butoxyphenoxy)propyl)morpholine hydrochloride C H NO .HCl; mol. wt.:329.87



What does Pramosone E Cream 2.5% look like?



What are the available doses of Pramosone E Cream 2.5%?

Sorry No records found.

What should I talk to my health care provider before I take Pramosone E Cream 2.5%?

Sorry No records found

How should I use Pramosone E Cream 2.5%?

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topical corticosteroids are generally applied to the affected area as a thin film three to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.


What interacts with Pramosone E Cream 2.5%?

Sorry No Records found


What are the warnings of Pramosone E Cream 2.5%?

Sorry No Records found


What are the precautions of Pramosone E Cream 2.5%?

Sorry No Records found


What are the side effects of Pramosone E Cream 2.5%?

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

BurningHypertrichosisMaceration of the skin
ItchingAcneiform eruptionsSecondary infection
IrritationHypopigmentationSkin atrophy
DrynessPerioral dermatitisStriae
FolliculitisAllergic contact dermatitisMiliaria



What should I look out for while using Pramosone E Cream 2.5%?

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.


What might happen if I take too much Pramosone E Cream 2.5%?

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See .)


How should I store and handle Pramosone E Cream 2.5%?

Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The product may be filtered using a sterile filter if particles are seen subsequent to opening of the ampoule.OPC ampoule: to open, turn so that the point faces upward and break off the neck with a downward movement.ArrayInspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The product may be filtered using a sterile filter if particles are seen subsequent to opening of the ampoule.OPC ampoule: to open, turn so that the point faces upward and break off the neck with a downward movement.ArrayInspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The product may be filtered using a sterile filter if particles are seen subsequent to opening of the ampoule.OPC ampoule: to open, turn so that the point faces upward and break off the neck with a downward movement.ArrayPramosone E Cream 2.5% Storage Conditions:Rx OnlyManufactured for Sebela Ireland Ltd.By Ferndale Laboratories, Inc., Ferndale, MI 48220 U.S.A.Distributed by Sebela Pharmaceuticals Inc. 645 Hembree Parkway, Suite I Roswell, GA 30076 www.sebelapharma.com Toll Free 1-844-732-3521 Pramosone E is a trademark of Sebela International Limited. ©2014 Reproduction prohibited Protected under U.S. Patent No. 5,635,497 #69921 PI 70895 0914 ©2014 Reproduction prohibited Pramosone E Cream 2.5% Storage Conditions:Rx OnlyManufactured for Sebela Ireland Ltd.By Ferndale Laboratories, Inc., Ferndale, MI 48220 U.S.A.Distributed by Sebela Pharmaceuticals Inc. 645 Hembree Parkway, Suite I Roswell, GA 30076 www.sebelapharma.com Toll Free 1-844-732-3521 Pramosone E is a trademark of Sebela International Limited. ©2014 Reproduction prohibited Protected under U.S. Patent No. 5,635,497 #69921 PI 70895 0914 ©2014 Reproduction prohibited Pramosone E Cream 2.5% Storage Conditions:Rx OnlyManufactured for Sebela Ireland Ltd.By Ferndale Laboratories, Inc., Ferndale, MI 48220 U.S.A.Distributed by Sebela Pharmaceuticals Inc. 645 Hembree Parkway, Suite I Roswell, GA 30076 www.sebelapharma.com Toll Free 1-844-732-3521 Pramosone E is a trademark of Sebela International Limited. ©2014 Reproduction prohibited Protected under U.S. Patent No. 5,635,497 #69921 PI 70895 0914 ©2014 Reproduction prohibited Pramosone E Cream 2.5% Storage Conditions:Rx OnlyManufactured for Sebela Ireland Ltd.By Ferndale Laboratories, Inc., Ferndale, MI 48220 U.S.A.Distributed by Sebela Pharmaceuticals Inc. 645 Hembree Parkway, Suite I Roswell, GA 30076 www.sebelapharma.com Toll Free 1-844-732-3521 Pramosone E is a trademark of Sebela International Limited. ©2014 Reproduction prohibited Protected under U.S. Patent No. 5,635,497 #69921 PI 70895 0914 ©2014 Reproduction prohibited Pramosone E Cream 2.5% Storage Conditions:Rx OnlyManufactured for Sebela Ireland Ltd.By Ferndale Laboratories, Inc., Ferndale, MI 48220 U.S.A.Distributed by Sebela Pharmaceuticals Inc. 645 Hembree Parkway, Suite I Roswell, GA 30076 www.sebelapharma.com Toll Free 1-844-732-3521 Pramosone E is a trademark of Sebela International Limited. ©2014 Reproduction prohibited Protected under U.S. Patent No. 5,635,497 #69921 PI 70895 0914 ©2014 Reproduction prohibited Pramosone E Cream 2.5% Storage Conditions:Rx OnlyManufactured for Sebela Ireland Ltd.By Ferndale Laboratories, Inc., Ferndale, MI 48220 U.S.A.Distributed by Sebela Pharmaceuticals Inc. 645 Hembree Parkway, Suite I Roswell, GA 30076 www.sebelapharma.com Toll Free 1-844-732-3521 Pramosone E is a trademark of Sebela International Limited. ©2014 Reproduction prohibited Protected under U.S. Patent No. 5,635,497 #69921 PI 70895 0914 ©2014 Reproduction prohibited Pramosone E Cream 2.5% Storage Conditions:Rx OnlyManufactured for Sebela Ireland Ltd.By Ferndale Laboratories, Inc., Ferndale, MI 48220 U.S.A.Distributed by Sebela Pharmaceuticals Inc. 645 Hembree Parkway, Suite I Roswell, GA 30076 www.sebelapharma.com Toll Free 1-844-732-3521 Pramosone E is a trademark of Sebela International Limited. ©2014 Reproduction prohibited Protected under U.S. Patent No. 5,635,497 #69921 PI 70895 0914 ©2014 Reproduction prohibited Pramosone E Cream 2.5% Storage Conditions:Rx OnlyManufactured for Sebela Ireland Ltd.By Ferndale Laboratories, Inc., Ferndale, MI 48220 U.S.A.Distributed by Sebela Pharmaceuticals Inc. 645 Hembree Parkway, Suite I Roswell, GA 30076 www.sebelapharma.com Toll Free 1-844-732-3521 Pramosone E is a trademark of Sebela International Limited. ©2014 Reproduction prohibited Protected under U.S. Patent No. 5,635,497 #69921 PI 70895 0914 ©2014 Reproduction prohibited


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pramoxine hydrochloride is a topical anesthetic agent which provides temporary relief from itching and pain. It acts by stabilizing the neuronal membrane of nerve endings with which it comes into contact.

Non-Clinical Toxicology
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

There has been a report of a patient who passed an orange rubbery precipitate in his stool the day after ingesting carbamazepine suspension immediately followed by Thorazine* solution. Subsequent testing has shown that mixing carbamazepine suspension and chlorpromazine solution (both generic and brand name) as well as carbamazepine suspension and liquid Mellaril, resulted in the occurrence of this precipitate. Because the extent to which this occurs with other liquid medications is not known, carbamazepine suspension should not be administered simultaneously with other liquid medicinal agents or diluents (see ).

Clinically meaningful drug interactions have occurred with concomitant medications and include (but are not limited to) the following:

General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area and under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free Cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See .)

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly the corticosteroid should be discontinued until the infection has been adequately controlled.

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).